Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
PR Newswire —
Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals,...